Vori^™

Indication:
Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of following fungal infections:
- Invasive aspergillosis
- Candidemia in non-neutropenics and other deep tissue Candida infections
- Esophageal candidiasis
- Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of or refractory to other therapy

Dosage & Administration:
Voriconazole Tablet is to be taken at least one hour before or one hour following a meal.
For Patients 40 kg or above
Loading Dose: 400 mg twice daily (for the first 24 hours)
Maintenance Dose: 200 mg twice daily (from the 2nd day)
For Patients less than 40 kg
Loading Dose: 200 mg twice daily (for the first 24 hours)
Maintenance Dose: 100 mg or 150 mg twice daily (from the 2nd day)

Dosage Adjustment:
For adults: If patient response is inadequate, the oral maintenance dose may be increased from 200 mg to 300 mg every 12 hours. For adult patients weighing less than 40 kg, the oral maintenance dose may be increased from 100 mg to 150 mg every 12 hours. If patients are unable to tolerate 300 mg orally every 12 hours, reduce the oral maintenance dose by 50 mg steps to a minimum of 200 mg every 12 hours (or to 100 mg every 12 hours for adult patients weighing less than 40 kg).

Treatment duration depends upon patients’ clinical and mycological response.

Preparation:
Vori™ 200 Tablet:: Each pack contains 10 Tablets (in Alu-PVC blister packaging)
Vori™ 50 Tablet:: Each pack contains 10 Tablets (in Alu-PVC blister packaging)